Flomoxef: Difference between revisions

Revision as of 05:17, 23 October 2010 editI dream of horses (talk \| contribs)Autopatrolled, Extended confirmed users, Page movers, New page reviewers, Pending changes reviewers, Rollbackers572,256 editsm Reverted edits by Pradyumna k m to last version by Arcadian (GLOO)← Previous edit		Revision as of 02:04, 11 January 2011 edit undoPashihiko (talk \| contribs)Extended confirmed users3,563 editsNo edit summaryNext edit →
Line 10:		Line 10:
	\| PubChem = 65864		\| PubChem = 65864
	\| DrugBank =		\| DrugBank =
			\| KEGG = D07963
	\| chemical_formula =		\| chemical_formula =
	\| C=15 \| H=18 \| F=2 \| N=6 \| O=7 \| S=2		\| C=15 \| H=18 \| F=2 \| N=6 \| O=7 \| S=2

Revision as of 02:04, 11 January 2011

Pharmaceutical compound

Flomoxef
Clinical data

ATC code	none
Identifiers
IUPAC name (6R,7R)-7-amino]-3- sulfanylmethyl]- 7-methoxy-8-oxo-5-oxa-1-azabicyclooct-2-ene-2-carboxylic acid
CAS Number	99665-00-6
PubChem CID	65864
KEGG	D07963
CompTox Dashboard (EPA)	DTXSID5048845
Chemical and physical data
Formula	C₁₅H₁₈F₂N₆O₇S₂
Molar mass	496.46 g/mol g·mol

Flomoxef (INN) is an oxacephem antibiotic.

It has been identified as second-generation and fourth generation.

Masuda Z, Kurosaki Y, Ishino K, Yamauchi K, Sano S (2008). "Pharmacokinetic analysis of flomoxef in children undergoing cardiopulmonary bypass and modified ultrafiltration". Gen Thorac Cardiovasc Surg. 56 (4): 163–9. doi:10.1007/s11748-007-0208-5. PMID 18401677. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Ito M, Ishigami T (1991). "The meaning of the development of flomoxef and clinical experience in Japan". Infection. 19 Suppl 5: S253–7. PMID 1783441.

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)

β-lactamase sensitive (1st generation)	Benzylpenicillin (G) Benzathine benzylpenicillin Procaine benzylpenicillin Phenoxymethylpenicillin (V) Propicillin Pheneticillin Azidocillin Clometocillin Penamecillin
β-lactamase resistant (2nd generation)	Cloxacillin (Dicloxacillin Flucloxacillin) Oxacillin Nafcillin Methicillin

Aminopenicillins (3rd generation)	Amoxicillin Ampicillin (Pivampicillin Hetacillin Bacampicillin Lenampicillin Metampicillin Talampicillin) Epicillin
Carboxypenicillins (4th generation)	Ticarcillin Carbenicillin / Carindacillin Temocillin
Ureidopenicillins (4th generation)	Piperacillin Azlocillin Mezlocillin
Other	Mecillinam (Pivmecillinam) Sulbenicillin

1st generation	Cefazolin Cefalexin Cefadroxil Cefapirin Cefazedone Cefazaflur Cefradine Cefroxadine Ceftezole Cefaloglycin Cefacetrile Cefalonium Cefaloridine Cefalotin Cefatrizine
2nd generation	Cefaclor Cefprozil Cefuroxime Cefuroxime axetil Cefamandole Cefonicid Ceforanide Cefuzonam Cephamycin (Cefoxitin Cefotetan Cefminox Cefbuperazone Cefmetazole) Carbacephem (Loracarbef)
3rd generation	Cefixime Ceftriaxone Cefotaxime Antipseudomonal (Ceftazidime Cefoperazone) Cefdinir Cefcapene Cefdaloxime Ceftizoxime Cefmenoxime Cefpiramide Cefpodoxime Ceftibuten Cefditoren Cefotiam Cefetamet Cefodizime Cefpimizole Cefsulodin Cefteram Ceftiolene Oxacephem (Flomoxef Latamoxef)
4th generation	Cefepime Cefozopran Cefpirome Cefquinome
5th generation	Ceftaroline fosamil Ceftolozane Ceftobiprole
Siderophore	Cefiderocol
Veterinary	Ceftiofur Cefquinome Cefovecin

Combinations

Lipopeptides	Insert into bacterial cell wall causing perforation and depolarization: Daptomycin Surfactin
Other	Inhibits PG elongation and crosslinking: Ramoplanin

Intracellular

Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
DADAL/AR inhibitors (Cycloserine)
bactoprenol inhibitors (Bacitracin)

Other